SRRK vs IMVT
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SRRK · Scholar Rock$46.94 ▲ 3.16%
IMVT · Immunovant$30.53 ▲ 7.54%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SRRK +59.8%
- IMVT +30.6%
Head to head
| Metric | SRRK | IMVT |
|---|---|---|
| Price | $46.94 | $30.53 |
| Change today | ▲ 3.16% | ▲ 7.54% |
| Market cap | $5.72B | $6.31B |
| Return, 3 months | -9.5% | -23.5% |
| Return, year to date | +6.6% | +20.1% |
| Return, 1 year | +62.1% | +30.7% |
| P/E (TTM) | – | – |
| P/B | 22.5 | 8.6 |
| P/E percentile vs own 5y | 26th | 48th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +0.1% | -27.0% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -167.8% | -80.1% |
| Analyst target vs. price | +49.1% | +63.1% |
| Analyst buy share | 93% | 80% |
| RSI (14) | 60 | 51 |
| 30-day volatility | 42.7% | 44.8% |
| Max drawdown, 1 year | -34.0% | -40.5% |
| Trend read | Mixed | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IMVT is the largest of the group by market value.
- SRRK has returned the most over the past year.
- SRRK has been the calmest stock over the last 30 days.